Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus

20th September 2019 Uncategorised 0

Novo Nordisk’s Rybelsus—or, as industry watchers know it, oral semaglutide—snared its FDA nod Friday to control blood sugar in Type 2 diabetes patients. And with the drug’s stellar data and head-to-head study wins against top products in the field, the green light is expected to majorly shake things up.

More: Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Source: fierce